Alimta Lung Cancer Label Expanded To Include Longer Use
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has set a high bar for maintenance indications, which allow longer term use. With overall survival data, Eli Lilly’s Alimta (pemetrexed) has met that hurdle and is now approved for longer use in first-line nonsquamous non-small cell lung cancer.
You may also be interested in...
Astellas Files Personalized Tarceva In First-line Lung Cancer With FDA
If successful, filing in EGFR-positive patients could give Roche/Astellas’ Tarceva a commercial boost, broadening erlotinib’s role in non-small-cell lung cancer.
Astellas Files Personalized Tarceva In First-line Lung Cancer With FDA
If successful, filing in EGFR-positive patients could give Roche/Astellas’ Tarceva a commercial boost, broadening erlotinib’s role in non-small-cell lung cancer.
Cancer Therapies Should Be Held To Higher Bar In Maintenance Setting, ODAC Says
In their review of Merck/Ariad’s Taltorvic (ridaforolimus) for sarcoma patients with stable disease, members of FDA’s Oncologic Drugs Advisory Committee suggested the nature of maintenance therapy necessitates that efficacy be more robust, and toxicities less of a concern, than in the treatment setting.